Guggenheim Capital’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-8,031
| Closed | -$2M | – | 2095 |
|
|
2020
Q3 | $2M | Sell |
8,031
-1,986
| -20% | -$625K | 0.01% | 897 |
|
|
2020
Q2 | $3.48M | Buy |
10,017
+1,449
| +17% | +$452K | 0.03% | 660 |
|
|
2020
Q1 | $2.29M | Sell |
8,568
-1,965
| -19% | -$608K | 0.02% | 724 |
|
|
2019
Q4 | $3.41M | Sell |
10,533
-1,595
| -13% | -$463K | 0.03% | 804 |
|
|
2019
Q3 | $3.31M | Buy |
12,128
+2,619
| +28% | +$960K | 0.03% | 798 |
|
|
2019
Q2 | $5.08M | Sell |
9,509
-699
| -7% | -$351K | 0.04% | 591 |
|
|
2019
Q1 | $5.14M | Buy |
10,208
+590
| +6% | +$350K | 0.04% | 596 |
|
|
2018
Q4 | $4.74M | Buy |
9,618
+466
| +5% | +$281K | 0.04% | 603 |
|
|
2018
Q3 | $8.37M | Buy |
9,152
+169
| +2% | +$144K | 0.05% | 437 |
|
|
2018
Q2 | $6.58M | Sell |
8,983
-32,974
| -79% | -$38M | 0.04% | 538 |
|
|
2018
Q1 | $66.9M | Buy |
41,957
+31,887
| +317% | +$41.1M | 0.16% | 157 |
|
|
2017
Q4 | $9.02M | Sell |
10,070
-3,099
| -24% | -$1.83M | 0.02% | 726 |
|
|
2017
Q3 | $4.74M | Sell |
13,169
-2,620
| -17% | -$820K | 0.01% | 1096 |
|
|
2017
Q2 | $4.63M | Sell |
15,789
-285
| -2% | -$82.4K | 0.01% | 1064 |
|
|
2017
Q1 | $5.66M | Sell |
16,074
-1,596
| -9% | -$359K | 0.02% | 946 |
|
|
2016
Q4 | $3.25M | Sell |
17,670
-2,971
| -14% | -$604K | 0.01% | 1290 |
|
|
2016
Q3 | $5.32M | Sell |
20,641
-3,003
| -13% | -$773K | 0.02% | 982 |
|
|
2016
Q2 | $5.05M | Sell |
23,644
-1,610
| -6% | -$360K | 0.02% | 994 |
|
|
2016
Q1 | $5.21M | Sell |
25,254
-21,589
| -46% | -$4.15M | 0.02% | 969 |
|
|
2015
Q4 | $11.8M | Sell |
46,843
-7,767
| -14% | -$1.6M | 0.03% | 689 |
|
|
2015
Q3 | $8.98M | Buy |
54,610
+4,395
| +9% | +$777K | 0.03% | 799 |
|
|
2015
Q2 | $9.42M | Buy |
50,215
+22,335
| +80% | +$3.84M | 0.02% | 862 |
|
|
2015
Q1 | $4.6M | Buy |
27,880
+7,597
| +37% | +$1.56M | 0.01% | 1201 |
|
|
2014
Q4 | $4.72M | Buy |
20,283
+2,324
| +13% | +$497K | 0.01% | 1152 |
|
|
2014
Q3 | $3.25M | Sell |
17,959
-334
| -2% | -$63.9K | 0.01% | 1430 |
|
|
2014
Q2 | $3.52M | Sell |
18,293
-3,395
| -16% | -$600K | 0.01% | 1397 |
|
|
2014
Q1 | $3.94M | Buy |
21,688
+1,129
| +5% | +$223K | 0.01% | 1273 |
|
|
2013
Q4 | $3.5M | Buy |
20,559
+969
| +5% | +$156K | 0.01% | 1300 |
|
|
2013
Q3 | $3.07M | Buy |
19,590
+2,481
| +15% | +$459K | 0.01% | 1351 |
|
|
2013
Q2 | $2.96M | Buy |
+17,109
| New | +$2.62M | 0.01% | 1309 |
|
Other funds holding NKTR
MC
BG
Guggenheim Capital's NKTR Position: Q4 2020 in Review
Guggenheim Capital sold out of Nektar Therapeutics (NKTR) in Q4 2020, closing a stake of 8,031 shares — an estimated $2M sold.
Guggenheim Capital first reported a position in NKTR in Q2 2013 and held it in 30 quarters. The position peaked at $66.9M in Q1 2018. 245 funds tracked by Wall St. Rank hold NKTR as of Q4 2020.
- Guggenheim Capital reported no remaining Nektar Therapeutics position as of Q4 2020 after selling out during the quarter.
- Guggenheim Capital sold 8,031 Nektar Therapeutics shares in Q4 2020, an estimated $2M.
- Guggenheim Capital first reported a position in Nektar Therapeutics in Q2 2013 and held it in 30 quarters.
- Guggenheim Capital's Nektar Therapeutics position peaked at $66.9M in Q1 2018.
- 245 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2020.
Based on Guggenheim Capital's 13F filing for Q4 2020, filed 16 Feb 2021.